Gynesonics Names Jiayu Chen, Ph.D., Vice President, Engineering and Advanced Technologies

Recognized Leader in Medical Device Product Development, Ultrasound
Technology

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development of
minimally invasive solutions for symptomatic uterine fibroids, today
announced that medical device executive Jiayu Chen, Ph.D., has been
named Vice President of Engineering and Advanced Technologies, effective
immediately. Dr. Chen reports directly to President and CEO Christopher
M. Owens.

Dr. Chen has more than 20 years of experience in the medical device
industry with a particular emphasis on product development from concept
to commercialization, IP development and ultrasound technology
evaluation. Most recently, from 2013 to the present, Dr. Chen was a
Chief Engineer at GE Ultrasound, a division of GE Healthcare. In that
role he provided technical leadership and guidance on innovation and
product strategies for research and development and clinical programs.

Prior to that, Dr. Chen spent 10 years (2003-2013) as Vice President of
Engineering at Sunnyvale, CA-based U-Systems Inc, a manufacturer of
ultrasound products for breast cancer applications that was purchased by
GE Healthcare in November 2012. Dr. Chen built and managed a
highly-talented engineering team and structured the company’s
intellectual properties, among other duties.

Dr. Chen and his team at U-Systems Inc. delivered the first Premarket
Approval (PMA) by the FDA of an automated breast ultrasound system.

“Jiayu’s proven track record of innovation along with his strategic
vision will add significant expertise to our current and future
technology platforms,” Owens said. “As we continue to thoughtfully scale
the organization, his depth of knowledge in ultrasound technology,
leadership and drive for collaboration will support new engineering
development and clinical solutions, enhancing our product offerings,
while creating a foundation of excellence. We look forward to working
with Jiayu and his contribution to the continued success of the
organization.”

Dr. Chen has a Masters of Science degree in mechanical engineering from
Tsinghua University in China and a doctorate in electrical engineering
from Pennsylvania State University.

About Sonata System

The Sonata™ System, the next generation of Gynesonics’ technology
platform (the previous generation referred to as VizAblate), uses
radiofrequency energy to ablate fibroids under intrauterine sonography
guidance. The Sonata™ System, including the SMART Targeting Guide,
enables the operator to target fibroids and optimize ablations within
them. Sonata™ System’s design provides a straightforward, transcervical
access for a uterus preserving, incision-free fibroid treatment. This
intrauterine approach is designed to avoid the peritoneal cavity. In
October 2014, Gynesonics announced FDA approval of the SONATA IDE
pivotal trial for their latest generation Sonata™ System.

About Gynesonics

Gynesonics is a women’s healthcare company focused on minimally invasive
solutions for symptomatic uterine fibroids. Gynesonics has developed the
Sonata™ System for the transcervical treatment of symptomatic uterine
fibroids under intrauterine sonography guidance. The Sonata™ System is
CE Marked and approved for sale in the European Union. Sonata™ System is
not available for sale in the United States. Gynesonics is a privately
held company with headquarters in Redwood City, CA.

Contacts

Gynesonics
Chris Owens, +1 650-216-3860
President and CEO
www.gynesonics.com